公开(公告)号：US20070073064A1

公开(公告)日：2007-03-29

申请号：US10574688

申请日：2004-10-07

申请人： Takumi Takeyasu ,  Yoshinori Sato ,  Minoru Imai ,  Mitsuru Sakai ,  Kenji Manabe ,  Yoshiyuki Matsumoto ,  Susumu Takeuchi ,  Asahi Kawana ,  Masahiro Koga ,  Mitsuharu Asahita

发明人： Takumi Takeyasu ,  Yoshinori Sato ,  Minoru Imai ,  Mitsuru Sakai ,  Kenji Manabe ,  Yoshiyuki Matsumoto ,  Susumu Takeuchi ,  Asahi Kawana ,  Masahiro Koga ,  Mitsuharu Asahita

IPC分类号： C07D403/02

CPC分类号： C07C237/44 ,  C07D403/06

摘要： There is provided an industrial production method of an aminopyrrolidine derivative having chemokine receptor antagonist activity represented by the following formula, a synthetic intermediate thereof and a production method thereof: wherein R11 is H, C1-C6 alkyl or C2-C7 alkanoyl; R12, R14, R15, R16 and R17 are H, halogen, optionally halogenated C1-C6 alkyl, optionally halogenated C1-C6 alkoxy, hydroxyl or C2-C7 alkoxycarbonyl; R23, R24, R25 and R26 are H, halogen, optionally halogenated C1-C6 alkyl, optionally halogenated C1-C6 alkoxy or hydroxyl; and R3 is H or C1-C6 alkyl.

摘要翻译： 提供了具有下式表示的趋化因子受体拮抗剂活性的氨基吡咯烷衍生物及其合成中间体及其制备方法的工业生产方法：其中R 11是H，C 1 C 6 -C 6烷基或C 2 -C 7烷酰基; R 12，R 14，R 15，R 16和R 17均为 H，卤素，任选卤代C 1 -C 6烷基，任意卤代C 1 -C 6烷氧基， 羟基或C 2 -C 7烷氧基羰基; R 23，R 24，R 25和R 26是H，卤素，任选卤代的C 1 -C 12烷基， C 1 -C 6烷基，任选卤代C 1 -C 6烷氧基或羟基; R 3是H或C 1 -C 6烷基。

公开(公告)号：US07517875B2

公开(公告)日：2009-04-14

申请号：US10511174

申请日：2003-04-16

申请人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

发明人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

IPC分类号： C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  A61K31/4523 ,  A61K31/454 ,  A61P11/06

CPC分类号： C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5415 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的化合物，其药学上可接受的酸加合物或其药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物，其可用于治疗或预防相关疾病 与CCR3，如哮喘和过敏性鼻炎。

公开(公告)号：US20070032525A1

公开(公告)日：2007-02-08

申请号：US10511174

申请日：2003-04-16

申请人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

发明人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

IPC分类号： A61K31/454 ,  C07D487/02

CPC分类号： C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5415 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides compounds represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的化合物，其药学上可接受的酸加合物或其药学上可接受的C 1 -C 6烷基加合物，以及药物组合物 包括它们作为有效成分，其可用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。

公开(公告)号：US07524841B2

公开(公告)日：2009-04-28

申请号：US10512339

申请日：2003-04-16

申请人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

发明人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

IPC分类号： C07D487/04 ,  C07D403/12 ,  C07D403/14 ,  A61K31/4523 ,  A61K31/454 ,  A61P11/06

CPC分类号： C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/517

摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的4,4-（二取代的）哌啶衍生物，其药学上可接受的酸加合物或其药学上可接受的C1-C6烷基加合物，以及包含它们作为有效成分的药物组合物， 可用于治疗或预防与CCR3相关的疾病，如哮喘和过敏性鼻炎。

公开(公告)号：US20070037851A1

公开(公告)日：2007-02-15

申请号：US10512339

申请日：2003-04-16

申请人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

发明人： Yoshiyuki Matsumoto ,  Minoru Imai ,  Yoshiyuki Sawai ,  Susumu Takeuchi ,  Akinobu Nakanishi ,  Kunio Minamizono ,  Tomonori Yokoyama

IPC分类号： C07D487/02 ,  A61K31/454

CPC分类号： C07D401/12 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/517

摘要： The invention provides low molecular compounds having activity which inhibits binding of CCR3 ligands to CCR3 on target cells, i.e. CCR3 antagonists. The invention also provides 4,4-(disubstituted)piperidine derivatives represented by formula (I) below, pharmaceutically acceptable acid adducts thereof, or pharmaceutically acceptable C1-C6 alkyl adducts thereof, as well as pharmaceutical compositions comprising them as effective ingredients, which are useful for treatment or prevention of diseases associated with CCR3, such as asthma and allergic rhinitis.

摘要翻译： 本发明提供具有抑制靶细胞CCR3拮抗剂上CCR3配体与CCR3结合的活性的低分子化合物。 本发明还提供由下式（I）表示的4,4-（二取代的）哌啶衍生物，其药学上可接受的酸加成物或药学上可接受的C 1 -C 6烷基 其加合物，以及包含它们作为有效成分的药物组合物，其可用于治疗或预防与CCR3相关的疾病，例如哮喘和过敏性鼻炎。

公开(公告)号：US07667036B2

公开(公告)日：2010-02-23

申请号：US11202035

申请日：2005-08-12

申请人： Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Kenichiro Kataoka ,  Dale Robert Mitchell ,  Donald James Simpson ,  Clifford John Harris ,  Joelle Le ,  Yuko Yamakoshi

发明人： Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Kenichiro Kataoka ,  Dale Robert Mitchell ,  Donald James Simpson ,  Clifford John Harris ,  Joelle Le ,  Yuko Yamakoshi

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P35/04 ,  A61P25/28

CPC分类号： C07D487/04

摘要： The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent MAPKAP-K2 inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for MAPKAP-K2 mediated disorder, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

摘要翻译： 由式I表示的吡唑并[1,5-a]嘧啶衍生物及其药学上可接受的盐表现出优异的MAPKAP-K2抑制活性。 因此，包含化合物作为有效成分的药物预期可用作MAPKAP-K2介导的病症如炎性疾病，自身免疫性疾病，破坏性骨病，癌症和/或肿瘤生长的治疗或预防剂。

公开(公告)号：US20090223828A1

公开(公告)日：2009-09-10

申请号：US12398818

申请日：2009-03-05

申请人： Hitoshi Muramatsu ,  Seiya Kunioka ,  Nobuyuki Suzuki ,  Akira Ishibashi ,  Minoru Imai ,  Manabu Suzuki ,  Masahiro Ogawa

发明人： Hitoshi Muramatsu ,  Seiya Kunioka ,  Nobuyuki Suzuki ,  Akira Ishibashi ,  Minoru Imai ,  Manabu Suzuki ,  Masahiro Ogawa

IPC分类号： C25D5/02

CPC分类号： C25D7/04 ,  C25D17/004

摘要： A plating method for pre-plating or plating a cylinder inner peripheral surface to be treated of a cylinder block by introducing treatment liquid to the cylinder inner peripheral surface by using a plating apparatus provided with a sealing jig having a sealing member and an electrode to which the seal jig is mounted includes the steps, which are performed successively: sealing the cylinder inner peripheral surface by bringing the sealing jig into contact with the cylinder inner peripheral surface; introducing the treatment liquid to the cylinder inner peripheral surface; and treating the cylinder inner peripheral surface by applying predetermined charge to the electrode of the plating apparatus and the cylinder block to thereby perform pre-plating or plating process in a state that a liquid to be treated fills a space including the cylinder inner peripheral surface. In the method, the treatment liquid introducing step is performed after confirmation of sealing by the sealing step.

摘要翻译： 一种电镀方法，用于通过使用具有密封构件和电极的电镀装置将处理液引入到缸体内周面来对汽缸体进行处理的汽缸内周面进行电镀或电镀， 安装密封夹具包括依次执行的步骤：通过使密封夹具与气缸内周面接触来密封气缸内周面; 将处理液引入气缸内周面; 以及通过向镀覆设备和气缸体的电极施加预定的电荷来处理气缸内周面，从而在待处理的液体填充包括气缸内周面的空间的状态下进行预镀或电镀处理。 在该方法中，在通过密封步骤确认密封之后进行处理液引入步骤。

公开(公告)号：US07557110B2

公开(公告)日：2009-07-07

申请号：US10547080

申请日：2004-03-01

申请人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Dale Mitchell ,  James Donald Simpson ,  John Clifford Harris ,  Joelle Le

发明人： Kenichiro Kataoka ,  Naotaka Suzuki ,  Tomomi Kosugi ,  Minoru Imai ,  Hiroaki Makino ,  Mika Takakuwa ,  Gen Unoki ,  Aiko Fujino ,  Yasuhiro Oue ,  Yuko Yamakoshi ,  Satoshi Sugiura ,  Robert Dale Mitchell ,  James Donald Simpson ,  John Clifford Harris ,  Joelle Le

IPC分类号： C07D487/04 ,  A61K31/519

CPC分类号： C07D487/04

摘要： The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

摘要翻译： 由式I表示的吡唑并[1,5-a]嘧啶衍生物及其药学上可接受的盐表现出优异的激酶抑制活性。 因此，包含化合物作为有效成分的药物预期可用作其中涉及激酶的蛋白激酶介导的病症的治疗或预防剂，例如炎性疾病，自身免疫疾病，破坏性骨病，癌症和/或肿瘤生长。

公开(公告)号：US06621038B2

公开(公告)日：2003-09-16

申请号：US09956229

申请日：2002-01-24

申请人： Yoshimi Onitsuka ,  Minoru Imai

发明人： Yoshimi Onitsuka ,  Minoru Imai

IPC分类号： B23K1000

CPC分类号： H05H1/34 ,  B23K15/00

摘要： A torch for powder plasma buildup welding capable of readily attaining welding in conformity to any size of a pipe material to be subjected to welding, any configuration thereof and the like. A torch head is replaceably connected to a torch body. The torch body is provided with a gap formation spacer member which is abutted against an inner peripheral surface of the pipe material to keep a distance between an opening of a convergent nozzle of the torch head and the inner peripheral surface of the pipe material substantially constant during buildup welding. Also, the torch body is provided with a deflection restraint spacer member which is abutted against the inner peripheral surface of the pipe material to prevent deflection of the torch body in the pipe material during buildup welding.

公开(公告)号：US09063233B2

公开(公告)日：2015-06-23

申请号：US12735878

申请日：2009-01-29

申请人： Eiji Matsumoto ,  Tetsuo Shibata ,  Minoru Imai

发明人： Eiji Matsumoto ,  Tetsuo Shibata ,  Minoru Imai

IPC分类号： G08B1/08 ,  G05B23/02 ,  G03B11/00 ,  H04B7/185 ,  H04W72/00 ,  H04B7/00 ,  G01T7/00 ,  H04B7/155 ,  H04B7/26 ,  H04W74/08 ,  H04W84/04

CPC分类号： G01T7/00 ,  H04B7/155 ,  H04B7/2606 ,  H04W74/08 ,  H04W84/047

摘要： An exposure management system includes dosimeters, wireless relay devices that wirelessly communicate with the dosimeters, and a monitoring device. The dosimeters are carried by workers for measuring exposure doses in a radiation management facility. The wireless relay devices transmit a monitor indication message that requests the dosimeters to provide respective responses that include information of measured exposure doses. The wireless relay devices receive the responses from the dosimeters by using allocated respective communication channels that are different from each other. Each dosimeter receives the monitoring indication message and generates a designated number of response times for providing a response to the monitor indication message, and determines a communication channel corresponding to each of the generated response times. The monitoring device is connected to the wireless relay devices for monitoring an exposure state of each of the workers through the wireless relay devices and dosimeters.

摘要翻译： 曝光管理系统包括剂量计，与剂量计无线通信的无线中继设备和监视设备。 剂量计由工人承担，用于在辐射管理设施中测量暴露剂量。 无线中继设备发送监视器指示消息，其请求剂量计提供包括测量的暴露剂量的信息的相应响应。 无线中继设备通过使用彼此不同的分配的各个通信信道来接收来自剂量计的响应。 每个剂量计接收监视指示消息，并产生指定数量的响应时间，用于向监视器指示消息提供响应，并且确定对应于所产生的每个响应时间的通信信道。 监视装置连接到无线中继装置，用于通过无线中继装置和剂量计来监测每个工人的曝光状态。